Miniatura

Fitxers

PIIS0959804922007808.pdf (1.22 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-12-01

Llicència de publicació

cc by (c) Argilés, Guillem et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/192003

A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.ejca.2022.09.037

Resum

Purpose: The purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients.Patients and methods: Patients with mCRC and progression during or within 3 months following their last standard chemotherapy regimen were randomised to receive the approved dose of regorafenib of 160 mg QD (arm A) or 120 mg QD (arm B) administered as 3 weeks of treatment followed by 1 week off, or 160 mg QD 1 week on/1 week off (arm C). The primary end-point was the percentage of patients with G3/G4 treatment-related adverse events (AEs) in each arm.Results: There were 299 patients randomly assigned to arm A (n = 101), arm B (n = 99), or arm C (n = 99); 297 initiated treatments (arm A n = 100, arm B n = 98, arm C n = 99: pop-ulation for safety analyses). G3/4 treatment-related AEs occurred in 60%, 55%, and 54% of patients in arms A, B, and C, respectively. The most common G3/4 AEs were hypertension (19, 12, and 20 patients), fatigue (20, 14, and 15 patients), hypokalemia (11, 7, and 10 pa-tients), and hand-foot skin reaction (8, 7, and 3 patients). Median overall survival was 7.4 (IQR 4.0-13.7) months in arm A, 8.6 (IQR 3.8-13.4) in arm B, and 7.1 (IQR 4.4-12.4) in arm C.Conclusions: The alternative regorafenib dosing schedules were feasible and safe in patients with mCRC who had been previously treated with standard therapy. There was a higher nu-merical improvement on the most clinically relevant AEs in the intermittent dosing arm, particularly during the relevant first two cycles.

Matèries

Càncer colorectal, Metàstasi, Administració de medicaments

Matèries (anglès)

Colorectal cancer, Metastasis, Administration of drugs

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

ARGILÉS, Guillem, MULET, Nuria, VALLADARES AYERBES, Manuel, VIÉITEZ, José m., GRÁVALOS, Cristina, GARCÍA ALFONSO, Pilar, SANTOS, Cristina, TOBEÑA, María, GARCÍA PAREDES, Beatriz, BENAVIDES, Manuel, CANO, María t., LOUPAKIS, Fotios, RODRÍGUEZ GARROTE, Mercedes, RIVERA, Fernando, GOLDBERG, Richard m., CREMOLINI, Chiara, BENNOUNA, Jaafar, CIARDIELLO, Fortunato, TABERNERO CATURLA, Josep, ARANDA, Enrique, FALCONE, Alfredo, Spanish Cooperative Group for the Treatment of Digestive Tumors
(TTD), UNICANCER GI, The REARRANGE investigators. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). _European Journal of Cancer_. 2022. Vol. 177, núm. 154-163. [consulta: 21 de gener de 2026]. ISSN: 0959-8049. [Disponible a: https://hdl.handle.net/2445/192003]

Exportar metadades

JSON - METS

Compartir registre